VistaGen Therapeutics (NASDAQ:VTGN) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of VistaGen Therapeutics (NASDAQ:VTGN) from a hold rating to a sell rating in a research note released on Saturday.

Other analysts also recently issued reports about the company. Jefferies Financial Group restated a “hold” rating and issued a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Stifel Nicolaus cut shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a research report on Wednesday, December 17th. Finally, William Blair reiterated a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Stock Up 1.2%

VTGN opened at $0.62 on Friday. The stock’s fifty day moving average is $0.60 and its two-hundred day moving average is $2.34. The company has a market capitalization of $24.42 million, a P/E ratio of -0.33 and a beta of 0.29. VistaGen Therapeutics has a 52 week low of $0.43 and a 52 week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.14 million. Equities analysts anticipate that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTGN. Tudor Investment Corp ET AL bought a new position in shares of VistaGen Therapeutics during the 4th quarter worth approximately $50,000. OMERS ADMINISTRATION Corp acquired a new stake in VistaGen Therapeutics in the fourth quarter valued at approximately $68,000. State Street Corp boosted its stake in VistaGen Therapeutics by 25.0% in the fourth quarter. State Street Corp now owns 121,114 shares of the company’s stock valued at $80,000 after acquiring an additional 24,256 shares in the last quarter. Millennium Management LLC purchased a new position in VistaGen Therapeutics in the third quarter worth $73,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in VistaGen Therapeutics in the third quarter worth $39,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.